Single daily dose of gentamicin in the treatment of pediatric urinary tract infection

Journal of the Medical Association of Thailand

Volumn 82, Issue SUPPL., 1999, Pages

  Tapaneya Olarn, Chaleomsri ^a   Tapaneya Olarn, Wiwat ^a   Pitayamornwong, Vichit ^a   Petchthong, Thanom ^a   Tangnararatchakit, Kanchana ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Gentamicin; Pediatric; Urinary Tract Infection

Indexed keywords

EID: 28144439854     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Deamer RL, Dial LK. The evolution of aminoglycoside therapy : a single daily dose. Am Fam Physician 1996; 53:1782-6.
2. John JF Jr. What price success? The continuing saga of the toxic: therapeutic ratio in the use of aminoglycoside antibiotics. J Infect Dis 1988; 158: 1-6.
3. Kapusnik JE, Hackbarth CJ, Chambers HF, Carpenter T, Sande MA. Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia. J Infect Dis 1988; 158:7-12 [Published erratum appears in J Infect Dis 1988; 158:911].
4. Davis BD. Mechanism of bactericidal action of aminoglycosides. Microbiol Rev 1987; 51:341-50 [Published erratum appears in Microbiol Rev 1988;52:153].
5. Moor RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis 1984; 149:443-8.
6. Noone P, Parsons TM, Pattison JR, Slack RC, Garfield-Davies D, Hughes K. Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. Br Med J 1974; 1:477-81.
7. Moore RD, Smith Cr, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med 1984; 77: 657-62.
8. Vogelman BS, Craig WA. Postantibiotic effects. J Antimicrob Chemother 1985; 15(Suppl):37-46.
9. MacKenzie FM, Gould IM. The post-antibiotic effect. J Antimicrob Chemother 1993; 32:519-37.
10. Chan GL. Alternative dosing strategy for aminoglycosides: impact on efficacy, nephrotoxicity, and ototoxicity. DICP 1989; 23:788-94.
11. Mattie HM, Craig WA, Pecheir JE. Determinants of efficacy and toxicity of aminoglycosides. J Antimicrob Chemother 1989; 24:281-93.
12. Leaback DH, Walker PG. Studies on glucosaminidase. Biochem J 1961; 78: 151-6.
13. Assadamongkol K, Tapaneya-Olarn W, Chatasingh S. Urinary N-acetyl-beta D-glucosaminidase (NAG) in aminoglycoside nephrotoxicity. J Med Assoc Thai 1989; 2(Suppl 1):42-5.
14. Prins JM, Buller HR. Kuijper EJ, Tange RA, Speelman P. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993; 341:325-9.
15. Elhanan K, Siplovich L, Raz R. Gentamicin once-daily versus thrice-daily in children. J Antimicrob Chemother 1995; 35:327-32.
16. Shanka AJ, Sharma S. Gentamicin as daily dose therapy in recurrent urinary tract infection in children. Curr Ther Res 1987; 41:599-603.
17. Viscoli C, Dudley M, Ferra G, et al. Serum concentrations and safety of single daily dosing of amikacin in children undergoing bone marrow transplantation. J Antimicrob Chemother 1991; 27(Suppl C):113-20.
18. Trijillo H, Robleclo J, Robeldo C, et al. Single daily dose amikacin in pediatric patients with severe gram-negative infections. J Antimicrob Chemother 1991; 27(Suppl C):141-7.